Skip to main content

ENGLISH · EVIDENCE OVERVIEW

PEG-MGF
evidence profile

Identity-sensitive PEGylated mechano-growth-factor product term related to IGF-1 splice biology. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

PEG-MGF: conceptual scientific illustration for Growth Hormone Biology
VISUAL GUIDE · PEG-MGF

Growth Hormone Biology

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

An identity-sensitive term that must separate endogenous IGF-1Ec expression, synthetic MGF E-peptide, full-length constructs and PEGylated products. FDA identified no human exposure data for PEG-MGF; endogenous exercise responses and non-PEG cell studies do not establish product efficacy or safety.

01

ENTITY FACTS

What should readers identify first?

MOLECULEPEG-MGF
PHARMACOLOGYIdentity-sensitive PEGylated mechano-growth-factor product term related to IGF-1 splice biology
PRIMECORE CLASSC
EVIDENCE GRADEU
RESEARCH TOPICGrowth Hormone Biology
LAST REVIEWED2026-08-29

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

Insufficient data in the current dataset

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. https://www.fda.gov/media/94155/download?attachment=
  3. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  4. https://pubmed.ncbi.nlm.nih.gov/12562960/
  5. https://pubmed.ncbi.nlm.nih.gov/19567392/
  6. https://pubmed.ncbi.nlm.nih.gov/21354439/
  7. https://pubmed.ncbi.nlm.nih.gov/24253050/
  8. https://pubmed.ncbi.nlm.nih.gov/26991004/
  9. https://pubmed.ncbi.nlm.nih.gov/25466910/
  10. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is PEG-MGF?

PEG-MGF is described pharmacologically as Identity-sensitive PEGylated mechano-growth-factor product term related to IGF-1 splice biology. An identity-sensitive term that must separate endogenous IGF-1Ec expression, synthetic MGF E-peptide, full-length constructs and PEGylated products. FDA identified no human exposure data for PEG-MGF; endogenous exercise responses and non-PEG cell studies do not establish product efficacy or safety.

Does PEG-MGF have strong evidence?

PrimeCoreBio records Evidence Grade U. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is PEG-MGF approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice